Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://gmeiner-verlag.de
Are you over 18 and want to see adult content?
A complete backup of https://meals.com
Are you over 18 and want to see adult content?
A complete backup of https://fotoclub-olpe.de
Are you over 18 and want to see adult content?
A complete backup of https://social-matic.com
Are you over 18 and want to see adult content?
A complete backup of https://noromoseley.com
Are you over 18 and want to see adult content?
A complete backup of https://comicbook.com
Are you over 18 and want to see adult content?
A complete backup of https://tlevels.gov.uk
Are you over 18 and want to see adult content?
A complete backup of https://xiti.com
Are you over 18 and want to see adult content?
A complete backup of https://inessa.com
Are you over 18 and want to see adult content?
A complete backup of https://crcindustries.com
Are you over 18 and want to see adult content?
A complete backup of https://ambition.org.uk
Are you over 18 and want to see adult content?
A complete backup of https://asplashofvanilla.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://nbwla.com
Are you over 18 and want to see adult content?
A complete backup of https://ftiab.se
Are you over 18 and want to see adult content?
A complete backup of https://5elementov.ru
Are you over 18 and want to see adult content?
A complete backup of https://saltcitysearch.com
Are you over 18 and want to see adult content?
A complete backup of https://wjcs.com
Are you over 18 and want to see adult content?
A complete backup of https://threefivetwo.com
Are you over 18 and want to see adult content?
A complete backup of https://berlin-marathon.com
Are you over 18 and want to see adult content?
A complete backup of https://kitchen.ci
Are you over 18 and want to see adult content?
A complete backup of https://advance.swiss
Are you over 18 and want to see adult content?
A complete backup of https://elizz.com
Are you over 18 and want to see adult content?
A complete backup of https://discoverlivesteam.com
Are you over 18 and want to see adult content?
Text
NANTKWEST.COM
Found. The document has moved here. NANTKWEST ANNOUNCES PHASE 1 RESULTS FOR FIRST-IN-HUMAN PD First-in-human trial shows no dose-limiting toxicities in six subjects treated as out-patients with PD-L1.t-haNK off-the-shelf CAR NK cell therapy with potential to overcome limitations ofNANTKWEST, INC.
Redirecting to https://ir.immunitybio.com. 0001564590-19-017179 The Investor Relations website contains information about Nantkwest, Inc.'s business for stockholders, potential investors, and financialanalysts.
SEC FILING - IMMUNITYBIO, INC. - IR.NANTKWEST.COM (1) See “Underwriting” for additional information regarding the compensation payable to the underwriters. We have granted the underwriters an option for a period of 30 days to purchase up to additional shares of our common stock at the public offering price, less the underwriting discounts and commissions.IR.NANTKWEST.COM
Redirecting to https://ir.immunitybio.com. 0001209191-16-109304 The Investor Relations website contains information about Nantkwest, Inc.'s business for stockholders, potential investors, and financialanalysts.
0001564590-18-028007 The Investor Relations website contains information about ImmunityBio, Inc.'s business for stockholders, potential investors, and financialanalysts.
NANTKWEST.COM
Found. The document has moved here. NANTKWEST ANNOUNCES PHASE 1 RESULTS FOR FIRST-IN-HUMAN PD First-in-human trial shows no dose-limiting toxicities in six subjects treated as out-patients with PD-L1.t-haNK off-the-shelf CAR NK cell therapy with potential to overcome limitations ofNANTKWEST, INC.
Redirecting to https://ir.immunitybio.com. 0001564590-19-017179 The Investor Relations website contains information about Nantkwest, Inc.'s business for stockholders, potential investors, and financialanalysts.
SEC FILING - IMMUNITYBIO, INC. - IR.NANTKWEST.COM (1) See “Underwriting” for additional information regarding the compensation payable to the underwriters. We have granted the underwriters an option for a period of 30 days to purchase up to additional shares of our common stock at the public offering price, less the underwriting discounts and commissions.IR.NANTKWEST.COM
Redirecting to https://ir.immunitybio.com. 0001209191-16-109304 The Investor Relations website contains information about Nantkwest, Inc.'s business for stockholders, potential investors, and financialanalysts.
0001564590-18-028007 The Investor Relations website contains information about ImmunityBio, Inc.'s business for stockholders, potential investors, and financialanalysts.
NANTKWEST, INC.
Redirecting to https://ir.immunitybio.com.IR.NANTKWEST.COM
Redirecting to https://ir.immunitybio.com. SEC FILING | NANTKWEST, INC. FORM 4: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 NANTKWEST PROVIDES UPDATE ON CLINICAL PROGRAMS AT BANK OF CULVER CITY, Calif.--(BUSINESS WIRE)--May 17, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, provided an update today on the company’s aNK, haNK and taNK clinical programs in a 0001209191-16-109304 The Investor Relations website contains information about Nantkwest, Inc.'s business for stockholders, potential investors, and financialanalysts.
0001564590-18-028007 The Investor Relations website contains information about ImmunityBio, Inc.'s business for stockholders, potential investors, and financialanalysts.
BANK OF AMERICA 2020 HEALTHCARE CONFERENCE The Investor Relations website contains information about ImmunityBio, Inc.'s business for stockholders, potential investors, and financialanalysts.
0001209191-19-020891 The Investor Relations website contains information about ImmunityBio, Inc.'s business for stockholders, potential investors, and financialanalysts.
NANTKWEST.COM
Found. The document has moved here. NANTKWEST ANNOUNCES PHASE 1 RESULTS FOR FIRST-IN-HUMAN PD First-in-human trial shows no dose-limiting toxicities in six subjects treated as out-patients with PD-L1.t-haNK off-the-shelf CAR NK cell therapy with potential to overcome limitations ofNANTKWEST, INC.
Redirecting to https://ir.immunitybio.com. 0001564590-19-017179 The Investor Relations website contains information about Nantkwest, Inc.'s business for stockholders, potential investors, and financialanalysts.
SEC FILING - IMMUNITYBIO, INC. - IR.NANTKWEST.COM (1) See “Underwriting” for additional information regarding the compensation payable to the underwriters. We have granted the underwriters an option for a period of 30 days to purchase up to additional shares of our common stock at the public offering price, less the underwriting discounts and commissions.IR.NANTKWEST.COM
Redirecting to https://ir.immunitybio.com. 0001209191-16-109304 The Investor Relations website contains information about Nantkwest, Inc.'s business for stockholders, potential investors, and financialanalysts.
0001564590-18-028007 The Investor Relations website contains information about ImmunityBio, Inc.'s business for stockholders, potential investors, and financialanalysts.
NANTKWEST.COM
Found. The document has moved here. NANTKWEST ANNOUNCES PHASE 1 RESULTS FOR FIRST-IN-HUMAN PD First-in-human trial shows no dose-limiting toxicities in six subjects treated as out-patients with PD-L1.t-haNK off-the-shelf CAR NK cell therapy with potential to overcome limitations ofNANTKWEST, INC.
Redirecting to https://ir.immunitybio.com. 0001564590-19-017179 The Investor Relations website contains information about Nantkwest, Inc.'s business for stockholders, potential investors, and financialanalysts.
SEC FILING - IMMUNITYBIO, INC. - IR.NANTKWEST.COM (1) See “Underwriting” for additional information regarding the compensation payable to the underwriters. We have granted the underwriters an option for a period of 30 days to purchase up to additional shares of our common stock at the public offering price, less the underwriting discounts and commissions.IR.NANTKWEST.COM
Redirecting to https://ir.immunitybio.com. 0001209191-16-109304 The Investor Relations website contains information about Nantkwest, Inc.'s business for stockholders, potential investors, and financialanalysts.
0001564590-18-028007 The Investor Relations website contains information about ImmunityBio, Inc.'s business for stockholders, potential investors, and financialanalysts.
NANTKWEST, INC.
Redirecting to https://ir.immunitybio.com.IR.NANTKWEST.COM
Redirecting to https://ir.immunitybio.com. SEC FILING | NANTKWEST, INC. FORM 4: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 NANTKWEST PROVIDES UPDATE ON CLINICAL PROGRAMS AT BANK OF CULVER CITY, Calif.--(BUSINESS WIRE)--May 17, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, provided an update today on the company’s aNK, haNK and taNK clinical programs in a 0001209191-16-109304 The Investor Relations website contains information about Nantkwest, Inc.'s business for stockholders, potential investors, and financialanalysts.
0001564590-18-028007 The Investor Relations website contains information about ImmunityBio, Inc.'s business for stockholders, potential investors, and financialanalysts.
BANK OF AMERICA 2020 HEALTHCARE CONFERENCE The Investor Relations website contains information about ImmunityBio, Inc.'s business for stockholders, potential investors, and financialanalysts.
0001209191-19-020891 The Investor Relations website contains information about ImmunityBio, Inc.'s business for stockholders, potential investors, and financialanalysts.
NANTKWEST ANNOUNCES PHASE 1 RESULTS FOR FIRST-IN-HUMAN PD First-in-human trial shows no dose-limiting toxicities in six subjects treated as out-patients with PD-L1.t-haNK off-the-shelf CAR NK cell therapy with potential to overcome limitations ofNANTKWEST.COM
Found. The document has moved here.NANTKWEST, INC.
Redirecting to https://ir.immunitybio.com. SEC FILING - IMMUNITYBIO, INC. - IR.NANTKWEST.COM (1) See “Underwriting” for additional information regarding the compensation payable to the underwriters. We have granted the underwriters an option for a period of 30 days to purchase up to additional shares of our common stock at the public offering price, less the underwriting discounts and commissions.IR.NANTKWEST.COM
Redirecting to https://ir.immunitybio.com. 0001209191-16-109304 The Investor Relations website contains information about Nantkwest, Inc.'s business for stockholders, potential investors, and financialanalysts.
0001564590-18-028007 The Investor Relations website contains information about ImmunityBio, Inc.'s business for stockholders, potential investors, and financialanalysts.
NANTKWEST ANNOUNCES PHASE 1 RESULTS FOR FIRST-IN-HUMAN PD First-in-human trial shows no dose-limiting toxicities in six subjects treated as out-patients with PD-L1.t-haNK off-the-shelf CAR NK cell therapy with potential to overcome limitations ofNANTKWEST.COM
Found. The document has moved here.NANTKWEST, INC.
Redirecting to https://ir.immunitybio.com. SEC FILING - IMMUNITYBIO, INC. - IR.NANTKWEST.COM (1) See “Underwriting” for additional information regarding the compensation payable to the underwriters. We have granted the underwriters an option for a period of 30 days to purchase up to additional shares of our common stock at the public offering price, less the underwriting discounts and commissions.IR.NANTKWEST.COM
Redirecting to https://ir.immunitybio.com. 0001209191-16-109304 The Investor Relations website contains information about Nantkwest, Inc.'s business for stockholders, potential investors, and financialanalysts.
0001564590-18-028007 The Investor Relations website contains information about ImmunityBio, Inc.'s business for stockholders, potential investors, and financialanalysts.
NANT CANCER VACCINE: AN ORCHESTRATION OF IMMUNOGENIC CELL NANT Cancer Vaccine: An Orchestration of Immunogenic Cell Death by Overcoming Immune Suppression and Activating Natural Killer (NK) and T Cell Therapy as ≥ 3rd-Line Treatment in Patients with Triple-Negative Breast Cancer (TNBC) or Head and Neck Squamous CellCarcinoma (HNSCC)
NANTKWEST, INC.
Redirecting to https://ir.immunitybio.com. 0001193125-20-177788 The Investor Relations website contains information about Nantkwest, Inc.'s business for stockholders, potential investors, and financialanalysts.
IR.NANTKWEST.COM
Redirecting to https://ir.immunitybio.com. SEC FILING | NANTKWEST, INC. FORM 4: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934NANTKWEST, INC.
I te m 1.01 E n tr y i n to a M ate r i al D e fi n i ti ve A gre e me n t. A s of A ugus t 21, 2020, N a nt K w e s t , Inc . (t he “ C om pa ny” ) e nt e re d i nt o a de fi ni t i ve c ol l a bora t i on a gre e m e nt (t he “ C ol l a bora t i on A gre e m e nt ” ) w i th
NANTKWEST, INC.
Table of Contents 9920 Jefferson Boulevard Culver City, California 90232 (310) 883-1300 To our S t oc khol de rs : We a re pl e a s e d t o i nvi t e you t o a t t e nd t he a nnua l m e e t i ng of s t oc khol de rs of N a nt K w e s t , Inc ., t o be he l d on T hurs da y, J une 6, 2019 a t 9: 30 a .m . NANTKWEST TO PRESENT DATA AT THE 58TH ANNUAL MEETING OF The Investor Relations website contains information about Nantkwest, Inc.'s business for stockholders, potential investors, and financialanalysts.
NANTKWEST TO PRESENT AT THE 37TH ANNUAL CANACCORD GENUITY About NantKwest Inc.. NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells NANTKWEST PROVIDES UPDATE ON CLINICAL PROGRAMS AT BANK OF CULVER CITY, Calif.--(BUSINESS WIRE)--May 17, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, provided an update today on the company’s aNK, haNK and taNK clinical programs in a NANT CANCER VACCINE: AN ORCHESTRATION OF IMMUNOGENIC CELL NANT Cancer Vaccine: An Orchestration of Immunogenic Cell Death by Overcoming Immune Suppression and Activating Natural Killer (NK) and T Cell Therapy as ≥ 3rd-Line Treatment in Patients with Triple-Negative Breast Cancer (TNBC) or Head and Neck Squamous CellCarcinoma (HNSCC)
NANTKWEST ANNOUNCES PHASE 1 RESULTS FOR FIRST-IN-HUMAN PD First-in-human trial shows no dose-limiting toxicities in six subjects treated as out-patients with PD-L1.t-haNK off-the-shelf CAR NK cell therapy with potential to overcome limitations of 0001193125-20-177788 The Investor Relations website contains information about Nantkwest, Inc.'s business for stockholders, potential investors, and financialanalysts.
SEC FILING | NANTKWEST, INC. FORM 4: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 0001209191-20-032930 The Investor Relations website contains information about ImmunityBio, Inc.'s business for stockholders, potential investors, and financialanalysts.
IR.NANTKWEST.COM
Redirecting to https://ir.immunitybio.com.NANTKWEST.COM
Found. The document has moved here. SEC FILING - IMMUNITYBIO, INC. - IR.NANTKWEST.COM (1) See “Underwriting” for additional information regarding the compensation payable to the underwriters. We have granted the underwriters an option for a period of 30 days to purchase up to additional shares of our common stock at the public offering price, less the underwriting discounts and commissions. NANTKWEST PROVIDES UPDATE ON CLINICAL PROGRAMS AT BANK OF CULVER CITY, Calif.--(BUSINESS WIRE)--May 17, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, provided an update today on the company’s aNK, haNK and taNK clinical programs in a DIRECT INJECTION OF CAR-ENGINEERED CD19.TANK CELLS CULVER CITY, Calif.--(BUSINESS WIRE)--Nov. 22, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, today announced that the Company’s abstract reviewing data on the company’s CD19.taNK NANT CANCER VACCINE: AN ORCHESTRATION OF IMMUNOGENIC CELL NANT Cancer Vaccine: An Orchestration of Immunogenic Cell Death by Overcoming Immune Suppression and Activating Natural Killer (NK) and T Cell Therapy as ≥ 3rd-Line Treatment in Patients with Triple-Negative Breast Cancer (TNBC) or Head and Neck Squamous CellCarcinoma (HNSCC)
NANTKWEST ANNOUNCES PHASE 1 RESULTS FOR FIRST-IN-HUMAN PD First-in-human trial shows no dose-limiting toxicities in six subjects treated as out-patients with PD-L1.t-haNK off-the-shelf CAR NK cell therapy with potential to overcome limitations of 0001193125-20-177788 The Investor Relations website contains information about Nantkwest, Inc.'s business for stockholders, potential investors, and financialanalysts.
SEC FILING | NANTKWEST, INC. FORM 4: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 0001209191-20-032930 The Investor Relations website contains information about ImmunityBio, Inc.'s business for stockholders, potential investors, and financialanalysts.
IR.NANTKWEST.COM
Redirecting to https://ir.immunitybio.com.NANTKWEST.COM
Found. The document has moved here. SEC FILING - IMMUNITYBIO, INC. - IR.NANTKWEST.COM (1) See “Underwriting” for additional information regarding the compensation payable to the underwriters. We have granted the underwriters an option for a period of 30 days to purchase up to additional shares of our common stock at the public offering price, less the underwriting discounts and commissions. NANTKWEST PROVIDES UPDATE ON CLINICAL PROGRAMS AT BANK OF CULVER CITY, Calif.--(BUSINESS WIRE)--May 17, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, provided an update today on the company’s aNK, haNK and taNK clinical programs in a DIRECT INJECTION OF CAR-ENGINEERED CD19.TANK CELLS CULVER CITY, Calif.--(BUSINESS WIRE)--Nov. 22, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, today announced that the Company’s abstract reviewing data on the company’s CD19.taNKNANTKWEST, INC.
Redirecting to https://ir.immunitybio.com. 0001564590-20-038096 Nantkwest INC SEC filing: Form 10-Q on 08/06/2020 (0001564590-20-038096). SEC FILING | NANTKWEST, INC. FORM 4: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934IR.NANTKWEST.COM
Redirecting to https://ir.immunitybio.com. 0001209191-19-060285 The Investor Relations website contains information about Nantkwest, Inc.'s business for stockholders, potential investors, and financialanalysts.
NANTKWEST TO PRESENT AT THE 37TH ANNUAL CANACCORD GENUITY About NantKwest Inc.. NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cellsNANTKWEST, INC.
Table of Contents 9920 Jefferson Boulevard Culver City, California 90232 (310) 883-1300 To our S t oc khol de rs : We a re pl e a s e d t o i nvi t e you t o a t t e nd t he a nnua l m e e t i ng of s t oc khol de rs of N a nt K w e s t , Inc ., t o be he l d on T hurs da y, J une 6, 2019 a t 9: 30 a .m . 0001564590-18-028007 The Investor Relations website contains information about ImmunityBio, Inc.'s business for stockholders, potential investors, and financialanalysts.
IR.NANTKWEST.COM
Document and Entity Information - shares. 3 Months Ended; Mar. 31,2019
IR.NANTKWEST.COM
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934* Our Science
* Platforms
* Pipeline
* Expanded Access
* Unique Approach
* Patients
* Trial Investigators* Researchers
* Therapies
* Pancreatic Cancer
* Merkel Cell Carcinoma * Non-Small Cell Lung Cancer * Triple Negative Breast Cancer* Bladder Cancer
* Glioblastoma
* HIV
* COVID-19
* Our Company
* About Us
* Careers
* Investor Relations* Contact
* Research
* News
* Get Started
* Join a Trial
* Open a Trial
* License Our Cells
Select Page
* Our Science
* Platforms
* Pipeline
* Expanded Access
* Unique Approach
* Patients
* Trial Investigators* Researchers
* Therapies
* Pancreatic Cancer
* Merkel Cell Carcinoma * Non-Small Cell Lung Cancer * Triple Negative Breast Cancer* Bladder Cancer
* Glioblastoma
* HIV
* COVID-19
* Our Company
* About Us
* Careers
* Investor Relations* Contact
* Research
* News
* Get Started
* Join a Trial
* Open a Trial
* License Our Cells
OUTSMART
YOUR DISEASE™
ImmunityBio is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. SOLUTIONS FOR RESEARCH SCIENTISTS Our NK-92® cell line provides a versatile bioanalytical testing solution that helps researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter geneassays.
Learn More
SOLUTIONS FOR PATIENTS Many therapies for treating cancer and infectious diseases severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.Learn More
OPPORTUNITIES FOR TRIAL INVESTIGATORS Natural killer cell-based immunotherapies are key to future cancer treatments. Our investigational NK-92®-engineered cells have demonstrated wide therapeutic potential across multiple tumor types, and, in clinical studies, have proven to be well-tolerated, making them ideal for clinical trial investigations.Learn More
SOLUTIONS FOR RESEARCH SCIENTISTS Our NK-92® cell line provides a versatile bioanalytical testing solution that helps researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter geneassays.
Learn More
SOLUTIONS FOR PATIENTS Many therapies for treating cancer and infectious diseases severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.Learn More
OPPORTUNITIES FOR TRIAL INVESTIGATORS Natural killer cell-based immunotherapies are key to future cancer treatments. Our investigational NK-92®-engineered cells have demonstrated wide therapeutic potential across multiple tumor types, and, in clinical studies, have proven to be well-tolerated, making them ideal for clinical trial investigations.Learn More
SOLUTIONS FOR RESEARCH SCIENTISTS Our NK-92® cell line provides a versatile bioanalytical testing solution that helps researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter geneassays.
Learn More
Dr. Patrick Soon-Shiong Executive Chairman, ImmunityBio At ImmunityBio, we envision a day when we no longer fear cancer, but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather thanjust the disease.
SMART THERAPIES FOR DIFFICULT DISEASES™ Our investigational immunotherapy products are tailored to each patient’s needs. We employ a “triangle” offense designed to deliver durable, complete responses in cancer and infectious diseases.Our Science
INVESTIGATIONAL CANCER THERAPIES ImmunityBio’s platform addresses the entire immune system beyond the limitations of chimeric antigen receptor T-cell (CAR-T) therapies and checkpoint inhibitors by activating the natural killer cell, T cells, macrophages, and inducing memory through dendritic cells. Clinical trials orchestrating these unique therapies, which harness both the innate and adaptive immune system, are in progress across multipletumor types.
Select a Cancer to Learn More Pancreatic Cancer Merkel Cell Carcinoma Non-Small Cell Lung Cancer Triple-Negative Breast CancerBladder Cancer
Glioblastoma
INVESTIGATIONAL VIRAL THERAPIES Infected cells, like cancer cells, can be exposed to enable recognition and killing by our natural killer cell and T cell platforms. Current clinical trials addressing HIV, COVID, and infectious diseases are in progress. A second-generation human adenovirus (hAd5) vector serves as a platform to deliver specific viral sequences and educate our immune system to clear the infected cells. The potential to administer these vaccines orally will enable greater global access. Select a Virus to Learn MoreHIV Covid-19
See All Research
IMMUNITYBIO IS CONTINUOUSLY PURSUING NEW IMMUNOTHERAPIES DESIGNED TO ATTACK DISEASE BY _ENHANCING_ THE PATIENT’S IMMUNE SYSTEM, NOTWEAKENING IT.
About Us
A ROBUST CLINICAL PIPELINE ImmunityBio's investigational immunotherapies are currently being studied for cancer and infectious diseases in a range of clinical trials at various stages.See Pipeline
LATEST NEWS & EVENTS Press Releases May 25, 2021 IMMUNITYBIO EXPANDS TRIALS OF T-CELL-BASED COVID-19 VACCINE CANDIDATE AS A ‘UNIVERSAL BOOST’ IN VACCINATED SUBJECTS AND RECEIVES APPROVAL TO TEST INTRANASAL SPRAY IN SOUTH AFRICA Studies will provide data on T-cell-based COVID-19 vaccine candidate as a universal boost with four potential routes...read more
Press Releases May 24, 2021 IMMUNITYBIO TO PRESENT AT THE JEFFERIES 2021 VIRTUAL HEALTHCARECONFERENCE
CULVER CITY, Calif., May 24, 2021 – ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today...read more
Press Releases May 20, 2021 IMMUNITYBIO TO PRESENT PRELIMINARY PHASE 2 DATA OF 68% DURABLE DISEASE CONTROL WITH ANKTIVA PLUS CHECKPOINT INHIBITOR IN FIRST 140 PATIENTS ENROLLED WITH LUNG CANCER AND MULTIPLE TUMOR TYPES WHO FAILED PRIOR CHECKPOINT THERAPY AT ASCO 2021 Chemotherapy free regimen (with NK and T cell activation via Anktiva) in patients across multiple tumor types who...read more
Visit Newsroom
QUICKLINKS
* Pipeline
* Careers
* News and Events
* Investor Relations* Contact
FOLLOW US
LEGAL
* Privacy Policy
* Legal Notice
* Patent Notice
2021 ImmunityBio, Inc. All Rights Reserved. A member of the NantWorks ecosystem of companies 'Nantkwest’, ‘Conkwest’, ‘aNK’, ‘haNK’, ‘taNK’, ‘vaNK’, ’t-haNK’, ‘ceNK’, ‘M-ceNK’, ‘NK-92’, ‘Neukosome’, ‘Living Drugs in a Bag’, and ‘Nature’s First Responder’ are trademarks or registered trademarks of Nantkwest,Inc.
Anktiva is a trademark of ImmunityBio, Inc. The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only. The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites. The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0